We used the zebrafish posterior lateral line (pLL) system to identify novel mediators of retrograde cargo transport in axons (Drerup and Nechiporuk, 2013). pLL axons develop early (axon extension is complete by 2 days post-fertilization (dpf) and synapse formation occurs by 4 dpf), are superficially localized and are largely planar, making them an ideal system for in vivo observations and manipulations (Figure 1A; Ghysen and Dambly-Chaudière, 2004; Metcalfe, 1985; Metcalfe et al., 1985). Using an ENU-based forward genetic screen, we isolated a larval-lethal, recessive mutant strain with large swellings in pLL axon terminals (Figure 1B). RNAmapper analysis (Miller et al., 2013) identified the causal mutation as a single nucleotide change (T to G) in the start codon of actr10. We confirmed actr10 as the affected gene using RNA-mediated rescue of axon terminal swellings and by performing TALEN- (Transcription Activator Like Effector Nuclease) mediated disruption of the first exon of actr10, which phenocopied the mutant axon terminal swellings (Figure 1C–F).

Figure 1

Download asset Open asset

Axonal swellings, like those observed in actr10 mutants, can arise due to a number of intracellular abnormalities, including disruptions in retrograde cargo transport (Drerup and Nechiporuk, 2013; Martin et al., 1999). To determine if a particular cargo was accumulating in actr10 mutant axon terminals, indicative of impaired retrograde movement, we performed immunolabeling on mutants and wildtype siblings at 4 dpf with antibodies against various axonal cargos. This revealed an accumulation of Cytochrome c, a mitochondrial protein, in actr10 axon terminals (Figure 2A,B,E). To confirm mitochondrial accumulation in mutant axon terminals, mitochondria were labeled in neurons with TagRFP by zygotic injection of a plasmid containing a mitochondrial targeting sequence tagged with this fluorescent protein (5kbneurod:mito-TagRFP). actr10 mutants displayed mitochondrial accumulation in pLL axon terminals (Figure 2C,D). Other known pLL axon retrograde cargos, including those labeled by Lamp1 (Lysosome associated membrane protein-1; late endosome/lysosome marker) and phosphorylated c-Jun N-Terminal Kinase (pJNK) did not accumulate (Figure 2F–K; Drerup and Nechiporuk, 2013). Expression of wildtype Actr10 using zygotic injection of in vitro synthesized mRNA rescued mitochondrial accumulation in actr10 mutants (Figure 2L–O), confirming that Actr10 is necessary for proper mitochondrial positioning.

Figure 2

Download asset Open asset

As our immunolabeling experiments were not exhaustive for every possible cargo in axons, we undertook transmission electron microscopy (TEM) analyses of pLL axon terminals to determine if mitochondria are the predominant cargo mislocalized in actr10 mutants. This experiment demonstrated mitochondria are highly enriched in the axon terminal swellings of actr10 mutants compared to other intracellular structures (Figure 3A,B; n = 3 wildtypes, n = 4 mutants). Together, our immunolabeling and TEM analyses showing mitochondrial accumulation in axon terminals could indicate interrupted retrograde mitochondrial transport in actr10 mutants.

Figure 3

Download asset Open asset

To determine if mitochondrial retrograde transport was disrupted in actr10 mutants, mitochondria in single pLL axons were tagged with TagRFP using 5kbneurod:mito-TagRFP plasmid injection and organelle movement was visualized by confocal microscopy (Figure 4A,B; Videos 1 and 2). Kymograph analysis demonstrated a 37% and 39% reduction in the distance moved by mitochondria in the anterograde and retrograde directions respectively in actr10 mutants but no change in mitochondrial transport velocity (Figure 4C–F). Despite the decrease in anterograde transport distance, the frequency of anterograde mitochondrial transport was unchanged in actr10 mutants. We also analyzed reversal frequency to determine if there was a defect in directional persistence of mitochondrial transport in actr10 mutants but found no difference in the proportion of mitochondria that reversed direction during our imaging sessions (wildtype: 0.011 ± 0.008; actr10 mutants: 0.000 ± 0.009; ANOVA; p=0.4003). In contrast, both the frequency of retrograde mitochondrial transport and the proportion of mitochondria moving in the retrograde direction were dramatically decreased in actr10 mutants (Figure 4G,H). As velocity of movement was largely normal, these data suggest a role for Actr10 in the attachment of mitochondria to the retrograde motor for transport.

Figure 4

Download asset Open asset

Video 1

Download asset

Video 2

Download asset

actr10 is ubiquitously expressed, albeit enriched in the nervous system during larval stages (Figure 5A–C). As neuronal activity and the presence of growth factors can modulate mitochondrial transport (Chada and Hollenbeck, 2004; Chen and Sheng, 2013), it was possible that changes in the axonal environment in actr10 mutants could alter mitochondrial movement. This led us to ask if Actr10 functions autonomously in axons to regulate mitochondrial transport. To test for a neuron-specific function for Actr10 in mitochondrial localization, we expressed monomeric red fluorescent protein (mRFP) tagged Actr10 in individual pLL neurons using zygotic injection of a 5kbneurod:mRFP-actr10 DNA plasmid and assessed axon terminals. While mRFP-Actr10 expression in wildtype axons had no apparent effects (Figure 5D; n = 6 in 3 biological replicates), it rescued axon terminal morphology and mitochondrial localization in all mutants analyzed (Figure 5E–G; n = 5 mutants in 3 biological replicates). These experiments confirmed a neuron-specific function for Actr10 in mitochondrial localization in axons.

Figure 5

Download asset Open asset

Previous work on Actr10 function assayed mitotic spindle positioning during cell division in cultured fibroblasts and nuclear positioning in fungi to show that Actr10 depletion phenocopied dynein loss of function (Lee et al., 2001; Yeh et al., 2012; Zhang et al., 2008). In association with structural work implicating Actr10 in Arp1 filament capping (Urnavicius et al., 2015), these data could imply that loss of Actr10 impacts dynactin integrity and, subsequently, all dynein function. However, the aforementioned work could also be interpreted to mean that appropriate dynactin-nuclear membrane interaction requires Actr10 function. Supporting this possibility, Actr10 has been shown to regulate dynactin-membrane association (Clark and Rose, 2006). With this data in mind, we next wanted to determine if loss of Actr10 phenocopied dynein or dynactin loss of function in mature neurons, the cell type that displayed specific defects in mitochondrial retrograde transport in our studies. First, we analyzed the localization of dynein and dynactin in actr10 mutant axons at 4 dpf. Neither Dynein heavy chain (DHC) nor p150 were significantly mislocalized in actr10 mutants, though we did observe a trend of increased DHC in actr10 mutant axon terminals (Figure 6A–F). Next, to determine if dynein was able to move in the retrograde direction, we assayed dynein motility by tagging the core motor complex using expression of an mRFP tagged variant of dynein light intermediate chain (5kbneurod:dync1li1V2-mRFP; Figure 6G,H; Videos 3 and 4). Kymograph analysis revealed no change in the parameters of retrograde dynein movement, though we did note a 42% reduction in the distance and a 26% reduction in the velocity of anterograde dynein transport. Despite these defects in anterograde dynein transport, there was no change in the proportion of dynein-positive puncta moving in the anterograde or retrograde direction in actr10 mutants at 4 dpf (Figure 6I–M). Additionally, we analyzed reversal frequency to determine if there was a defect in persistence of dynein movement in actr10 mutants but found no difference in the average number of puncta that reversed direction during our imaging sessions (wildtype: 1.62/100 µm*min ±0.37; actr10 mutants: 1.74/100 µm*min ±0.44; ANOVA; p=0.844). These experiments demonstrated that loss of Actr10 does not impede dynein-dynactin complex localization or dynein retrograde movement in axons.

Figure 6

Download asset Open asset

Video 3

Download asset

Video 4

Download asset

We then analyzed the stability of dynein-dynactin interaction using co-immunoprecipitation from whole larval extracts. Immunoprecipitation of endogenous proteins was not possible due to lack of zebrafish-specific antibodies, so we turned to overexpression of tagged dynein components using zygotic injection of in vitro synthesized mRNA. First, we confirmed that a GFP tagged version of dynein intermediate chain 2b (i2b), a core dynein protein, could integrate into the motor complex. mRNA encoding i2b-GFP was injected into zygotes and anti-GFP antibodies were used to immunoprecipitate the complex. Extracts were subjected to western blot analysis and probed with anti-DHC antibodies. i2b-GFP can integrate into the core dynein complex (Figure 6N). We then used this approach to determine if loss of Actr10 impacts dynein-dynactin interaction. i2b-GFP was expressed in actr10 mutants and wild-type siblings and larval extracts were subjected to GFP-based immunoprecipitation at 4 dpf. Western blot of larval extracts revealed no change in p150 interaction with the core dynein motor (Figure 6O). Together, these experiments confirmed that loss of Actr10 does not impact dynein-dynactin interaction.

To further explore the effect of loss of Actr10 on retrograde cargo transport, we analyzed the movement of additional dynein cargos in axons. First, we visualized peroxisome transport in lateral line axons (Videos 5 and 6). Kymograph analysis of peroxisome transport at 4 dpf demonstrated small changes in anterograde transport velocity and distance of retrograde transport bouts (Figure 7A–G). A slight, but not significant decrease in the proportion of peroxisomes moving in the retrograde was apparent as well (Figure 7G; ANOVA; p=0.07). Upon further investigation, we found that previous studies revealed a surprising relationship between mitochondria and peroxisomes, including a large number of shared membrane proteins, such as Drp1 (reviewed in Schrader, 2006). Our work implicates Drp1 in Actr10-dependent mitochondrial localization (see Figure 12), making the impact of Actr10 loss of function on peroxisome transport complex. Therefore, we analyzed the transport of a third cargo, Lamp1-labeled vesicles, which are composed of late endosomes and lysosomes. Analysis of Lamp1-positive vesicle movement at 4 dpf demonstrated that this cargo is transported normally in actr10 mutant axons (Figure 7H–L). These live imaging experiments, in conjunction with the immunolabeling of known retrograde cargos (Figure 2) and our TEM studies (Figure 3), argue that loss of Actr10 does not hinder the transport of all dynein-dependent, retrograde cargos in axons.

Figure 7

Download asset Open asset

Video 5

Download asset

Video 6

Download asset

Since we observed small changes in retrograde peroxisome transport, we wanted to further investigate the relationship between loss of Actr10 and loss of dynein/dynactin. To do this, we analyzed the ability of DHC and p150 null mutants to phenocopy actr10 mutants. First, we compared actr10 mutants to a previously isolated zebrafish DHC mutant, dync1h1^mw20 (hereafter referred to as dync1h1; Insinna et al., 2010). Unlike actr10 mutants (see Figure 1), dync1h1 mutants displayed rapid degeneration of pLL axons by 4 dpf, with pLL nerves extending less than half-way to the tail at this time-point (Figure 8A,B). Mitochondria do accumulate in distal axons of dync1h1 mutants, as expected with global disruption of retrograde transport (Figure 8F,G). The disparity between actr10 and dync1h1 mutant axonal phenotypes argues that loss of Actr10 does not impact all dynein function in axons.

Figure 8

Download asset Open asset

We then compared the actr10 mutant phenotype to loss of dynein-dynactin interaction using zebrafish p150 mutants. There are two orthologs of p150 in zebrafish, p150a and p150b. These paralogues are highly similar at the amino acid level but have slightly different expression patterns: while both are ubiquitously expressed, p150b is enriched in developing (1 and 2 dpf) and mature (4 dpf) neurons while p150a is enriched only in mature neurons 4 dpf (Figure 9A–F). To determine whether loss of p150 phenocopies the actr10 mutant, we assayed single and double p150 mutants using a p150a mutant described previously (Del Bene et al., 2008; Wehman et al., 2005) and a novel p150b mutant we engineered (p150b^nl16). Loss of p150a alone has no discernable effect on axons or mitochondrial localization (Figure 8C,H). We used CRISPR-Cas9 technology (Hwang et al., 2013) to create a deletion in exon 3 of p150b, which resulted in a frame-shift and premature stop site. p150b single mutants are indistinguishable from wild-type siblings at 4 dpf, with normal axon terminals and no abnormalities in mitochondrial localization (Figure 8D,I). This strain does not have the small eye phenotype observed in dync1h1 and p150a mutants (Figure 8A–D; Del Bene et al., 2008; Insinna et al., 2010; Wehman et al., 2005). Unlike single p150 mutants, p150a/b mutants are phenotypically similar to dync1h1 mutants, with truncated pLL axons and mitochondrial accumulation at axon ends (Figure 8E,J). This confirms the reliance of mitochondria on the dynein-dynactin complex for retrograde movement and demonstrates that actr10 mutants do not phenocopy the axon truncation phenotype of dynein or dynactin loss of function mutants.

Figure 9

Download asset Open asset

We then analyzed the effect of p150 loss of function on mitochondrial transport in pLL axons. Mitochondria were tagged with TagRFP using zygotic injection of the 5kbneurod:mito-TagRFP plasmid and kymograph analysis was performed on videos acquired through live imaging (Figure 8K–N). Unlike loss of Actr10, p150a/b double mutants had an almost complete cessation of mitochondrial movement in the anterograde and retrograde directions (Figure 8N,O). In addition, we noted a dramatic loss of mitochondria from the central portion of axons in p150a/b double mutants, likely because of the strong defect in anterograde mitochondrial transport (Figure 8P). Analyses of transport parameters revealed no change in the distance or velocity of the residual mitochondrial movement in either direction (Figure 8Q,R). The dramatic loss of all mitochondrial movement in p150a/b mutants, specifically reductions in both the anterograde and retrograde pools, is not observed in actr10 mutants, which have only a reduction in the retrograde mitochondrial pool (see Figure 4). Furthermore, two cargos known to localize normally in actr10 mutants, pJNK and Lamp1 (see Figure 2), accumulate in in p150a/b mutant axon terminals (Figure 10A–D), indicating that the retrograde transport of these cargos is perturbed by loss of dynein-dynactin interaction. Therefore, our phenotypic, in vivo transport, immunolabeling and biochemical data fail to support the argument that loss of Actr10 impacts all dynein-dynactin function in axons and, instead, supports a specific requirement for Actr10 in mitochondrial retrograde transport in this neuronal compartment.

Figure 10

Download asset Open asset

The specific effect of Actr10 depletion on retrograde mitochondrial transport frequency led us to ask if Actr10 is necessary to attach this organelle to the dynein motor complex. We addressed this question using mitochondrial fractionation from whole larvae (Figure 11A; Prudent et al., 2013). Analysis of fractions revealed equal levels of p150 in the input and heavy fractions between wildtype and actr10 mutants. Strikingly, in actr10 mutants, p150 was largely lost from the mitochondrial fraction with a concomitant increase of p150 to the light fraction, which contains all cellular components not pelleted under low centrifugation speeds (Figure 11B,C). This result demonstrates the necessity of Actr10 for mitochondrial attachment to dynactin.

Figure 11

Download asset Open asset

To better define the mechanism of dynactin-Actr10-mitochondrial interaction, we identified the domain in Actr10 necessary for association with the dynactin complex using immunoprecipitation of deletion constructs (overlapping deletion of 40 amino acid regions) from HEK293T cells. Whereas Actr10△7–△10 deletions showed reduced binding to dynactin, Actr10△7 most consistently failed to immunoprecipitate dynactin in all experiments (Figure 11E,F; n = 4). As this result was somewhat variable in HEK cells, we confirmed the necessity of this domain for Actr10-dynactin interaction in vivo using immunoprecipitation of Actr10 and Actr10△7 from embryo lysates. This revealed a loss of interaction between Actr10△7 and dynactin, demonstrating the reliance of Actr10 on this region for interaction with dynactin (Figure 11G; n = 3). Finally, if Actr10 is a part of the scaffold necessary for mitochondria-dynactin interaction, a separate mitochondrial binding domain likely exists in Actr10. If this is the case, Actr10 lacking the dynactin binding domain should maintain its interaction with mitochondria. To address this, we assayed the ability of Actr10△7 to bind mitochondria using mitochondrial fractionation. mRFP-Actr10 and mRFP-Actr10△7, expressed using zygotic microinjection of respective mRNAs, were both present in the mitochondrial fractionation (Figure 11D,H; n = 2), arguing that separate protein domains exist in Actr10 which are necessary for interaction with dynactin and mitochondria. This data supports a role for Actr10 in binding mitochondria to dynactin for retrograde mitochondrial transport.

It is unlikely that Actr10 binds directly to mitochondria as it does not have predicted transmembrane or other membrane-associated domains. Rather, similar to Kinesin-1-mitochondrial attachment, there are likely partner proteins that facilitate this interaction (Glater et al., 2006; Guo et al., 2005). Literature searches revealed a particularly strong association between Drp1 (Dynamin related protein 1), a GTPase associated with mitochondrial fission, and mitochondrial localization. Specifically, a lysine to alanine mutation at amino acid 38 in Drp1 (mimicking a constitutively GDP-bound form) causes clustering of mitochondria in the perinuclear region of fibroblasts in a microtubule-dependent manner (Smirnova et al., 2001; Varadi et al., 2004). Using immunoprecipitation, we demonstrated that Drp1 interacts with Actr10, with strongly enhanced interaction between Actr10 and the Drp1^K38A variant (Figure 12A; n = 3 replicates in independent experiments; (Smirnova et al., 2001, 1998).

Figure 12

Download asset Open asset

Next, we asked whether Drp1 works with Actr10 to regulate mitochondrial retrograde transport in vivo. To address this, we examined the genetic interaction between Drp1 and Actr10 in mitochondrial localization in pLL neurons. We reasoned that if Drp1 and Actr10 function in the same pathway, Drp1 manipulation would impact the location of mitochondria in wildtype but not actr10 mutant axons. We expressed Drp1-mRFP, Drp1^K38A-mRFP, and cytoplasmic mRFP (control) in pLL neurons using injection of a plasmid encoding the respective open reading frame under an inducible promotor. Mitochondria were labeled by 5kbneurod:mito-EGFP co-injection. In wild-type larvae, expression of Drp1^K38A-mRFP caused mitochondrial clustering in the perinuclear region, phenotypically similar to the results observed in cultured fibroblasts (Figure 12B,C; Smirnova et al., 2001; Varadi et al., 2004). In contrast, Drp1^K38A-mRFP expression did not alter mitochondrial localization in actr10 mutant pLL neurons (Figure 12D,E). If Drp1^K38A mediates retrograde mitochondrial movement, we predicted its expression would induce movement of mitochondria from the proximal axon into the cell body, leading to loss of mitochondrial occupation of the axon. Indeed, expression of Drp1^K38A caused a substantial decrease in the number of mitochondria per micron in wildtype but not actr10 mutant axons (Figure 12F–J). Notably, actr10 mutants already have reduced mitochondrial occupation of pLL axons which could impact the fraction of mitochondria capable of motility in this assay. More definitive analyses of Drp1’s role in Actr10-dependent mitochondrial motility will be the subject of continued investigation. Together, the biochemical and genetic interaction between Actr10 and Drp1^K38A support a model in which Drp1, in its GDP-bound state, modulates dynein-based mitochondrial localization via an Actr10-dependent mechanism.

We provide multiple pieces of evidence supporting a function for Actr10 in mitochondrial transport. First, mitochondria are the only cargo analyzed whose localization or retrograde transport is significantly perturbed with loss of Actr10. If dynein-mediated cargo movement was generally disrupted, other cargos, including lysosomes and dynein itself, would fail to move in the retrograde direction as well. Second, the axonal phenotype of dynactin and dynein loss-of-function mutants is vastly different from actr10 mutants: dync1h1 and p150a/b mutants display pLL nerve degeneration at 4 dpf while actr10 mutants do not. Third, loss of dynactin-dynein interaction in p150a/b mutants impedes all mitochondrial transport, a phenotype that is not observed in actr10 mutants. Fourth, neither the localization of dynein and dynactin nor the retrograde movement of dynein are perturbed with loss of Actr10. Lastly, we identified a domain in Actr10 (△7) that is essential for interaction with the dynactin complex but inconsequential for interaction with mitochondria. This piece of data is critical as it demonstrates that Actr10 can interact with this organelle independently of dynactin, arguing for a direct role for this protein in mitochondria-dynactin interaction. Together, our data argue that Actr10 is necessary for dynactin-dependent, retrograde transport of mitochondria in axons.

Actr10 could directly link mitochondria to dynactin or potentially facilitate this interaction through other dynactin pointed end proteins, such as p62. p62 is of particular interest in this regard as it is predicted to rely on Actr10 for binding to the dynactin complex (Urnavicius et al., 2015). Based on our current data, we cannot rule out a role for this protein in mitochondrial transport. Furthermore, Actr10 interacting proteins, including p62, could have additional impacts on mitochondrial transport parameters, including transport distance. As noted above, actr10 mutants have slight deficits in the distance moved by mitochondria in both the anterograde and retrograde directions. While we cannot definitively ascertain the underlying mechanism of this disruption, at least three possibilities exist. First, bidirectional transport distance could be affected by the abnormal localization of mitochondria. Mitochondrial localization directly affects local levels of ATP, which in turn could compromise the processive activity of ATP-dependent motors necessary for long distance transport. Another possibility is local deficits in mitochondrial activity: if mitochondrial health is compromised, this could account for the bidirectional transport deficits of mitochondria. Finally, it is possible that Actr10 or its interacting proteins, such as p62, regulate motor engagement. It is largely thought that cargos typically have anterograde and retrograde motors attached simultaneously and direction of transport is attributed to regulation of motor engagement. More frequent oscillations in motor engagement due to loss of Actr10 or Actr10 interactors could account for the shortened distances moved by mitochondria in both directions. At this point, we do not have a full explanation for these transport parameter alterations but they are a topic of continued interest.

Our data does not preclude a function for Actr10 in the retrograde transport of additional cargos in axons or other roles for Actr10, which could vary based on a number of factors including cell type and developmental stage. Of particular interest is a potential role for Actr10 in peroxisome transport through interaction with Drp1. While we did not find a statistically significant difference in the proportion of peroxisomes moving in the retrograde direction, there was a trend towards a decrease in this population. As Drp1 is known to localize to peroxisome membranes as well (Schrader, 2006), it will be interesting to further explore the interplay between these proteins and the transport of these highly related organelles. In addition to cargo transport, one predicted function for Actr10, based on structural and biochemical data, is in capping the Arp1 filament (Urnavicius et al., 2015). In support of this role, knockdown of Actr10 using siRNA in Cos7 cells resulted in dissociation of the dynactin complex pointed end (Yeh et al., 2012). Additionally, studies in the fungi neurospora and aspergillus demonstrated that loss of Actr10 phenocopies the abnormal nuclear positioning observed with loss of dynein (Lee et al., 2001; Zhang et al., 2008). Similarly, zebrafish actr10 mutants display the small eye phenotype observed in dync1h1 and p150a mutants (see Figure 8 and Del Bene et al., 2008; Insinna et al., 2010). Finally, similar to loss of p150, knockdown of Actr10 resulted in multipolar spindle formation in Cos7 cells (Yeh et al., 2012). Together, these data could imply that Actr10 is in fact necessary for all dynein-dynactin activity through stabilizing the Arp1 filament; however, they could also be interpreted to mean that Actr10 is necessary for regulation of Arp1-membrane interaction. Indeed, Actr10 has been shown to regulate Arp1-membrane interaction (Clark and Rose, 2006) and the zebrafish eye phenotype in the p150a mutant is due to a defect in interkinetic nuclear migration (Del Bene et al., 2008). This type of function for Actr10 could also explain the nuclear positioning defect in the actr10 loss of function studies in fungi (Lee et al., 2001; Zhang et al., 2008). Therefore, rather than purely serving a stabilizing role for the dynactin complex, Actr10 may modulate both Arp1 interaction with the nuclear membrane and mitochondria-dynactin binding in axons. How these functions are disparately regulated in different cell types, in different cellular compartments and/or at varying developmental stages is still unclear.

Given the previous data implicating Actr10 in Arp1 capping and subsequent dynactin stability and dynein function (Urnavicius et al., 2015; Yeh et al., 2012; Zhang et al., 2008), we were presented with the challenge of confirming that Actr10 has a specific function in mitochondrial retrograde transport and reconciling our work with these previous studies. As outlined above, our evidence for a role for Actr10 in mitochondrial transport specifically includes: (1) actr10 mutant axons are not phenotypically identical to dync1h1 or p150 mutants; (2) mitochondrial retrograde, but not anterograde, transport is disrupted in actr10 mutants while all mitochondrial movement is inhibited in p150a/b mutants; and (3) localization and transport of all other cargos are not disrupted in actr10 mutants. Together, these results argue that loss of Actr10 does not impact all dynein-dynactin function. In addition, a variant of Actr10 lacking the dynactin binding domain retains its ability to interact with mitochondria, further substantiating a direct role for this protein in mitochondria-dynactin interaction. Together, our data argue that Actr10 participates in mitochondrial attachment to the retrograde motor protein complex in neurons in addition to potentially facilitating Arp1 capping and nuclear positioning in other contexts.

The interaction between Drp1 and Actr10 in mitochondrial retrograde transport may provide a link between mitochondrial movement and mitochondrial fission. Originally, we investigated the role of Drp1 in retrograde mitochondrial transport as previous studies revealed the unique ability of this GTPase to elicit mitochondrial localization to microtubule minus ends (Smirnova et al., 2001, 1998). Upon further investigation, it became apparent that a select number of proteins implicated in mitochondrial fission and fusion, including Drp1, have been shown to be essential for mitochondrial transport. Specifically, the fusion-related protein Mitofusin binds to the Miro-Milton complex and is necessary for mitochondrial movement (Misko et al., 2010). Similar to Miro and Milton, loss of Mitofusin results in decreased anterograde and retrograde mitochondrial transport in cultured neurons (Misko et al., 2010). Interestingly, the inner mitochondrial membrane protein Opa1, also necessary for mitochondrial fusion, does not participate in transport (Misko et al., 2010). Thus, eliminating mitochondrial fusion itself does not impact mitochondrial movement; rather mitochondrial outer membrane proteins may have dual roles in fusion-fission dynamics and transport.

Similarly, our work in conjunction with other studies supports the argument that Drp1 participates in both mitochondrial fission and retrograde mitochondrial transport. Drp1 translocates to mitochondria where it can bind to receptors Fis1 and Mff (LosonLosón et al., 2013). In its GTP-bound form, it then oligomerizes, forming a constrictable collar necessary for fission during which GTP is exchanged for GDP (Ingerman et al., 2005). We found that a Drp1 variant incapable of binding GTP stimulates mitochondrial accumulation at the nuclear periphery, linking fission with transport. Our genetic interaction data suggest that Actr10 functions with Drp1 in this process, though further experiments are necessary to confirm this. Rather than Actr10 working with Drp1 to regulate mitochondrial localization, it is also possible that loss of Actr10 results a decrease in the motile pool of mitochondria in axons upon which Drp1^K38A could work. We cannot differentiate between these possibilities at this point. Nevertheless, given the intriguing data generated here, it is tempting to speculate that, upon the GTP-GDP transition, not only do mitochondria undergo fission but Drp1 also recruits the retrograde motor protein complex through interaction with Actr10 to facilitate separation of these daughter mitochondria. The precise nature of Drp1-Actr10 interaction and the role of this interaction in mitochondrial retrograde transport is a subject of current investigation.

The coordinated regulation of mitochondrial transport is necessary for the formation and maintenance of active neural circuits. Our work identifies Actr10 as a crucial protein for mitochondrial interaction with the dynein-dynactin complex, regulating retrograde transport. In addition, we argue that the role of Actr10 is specific and not due to a general loss of dynactin stability or dynein function. The strongest pieces of evidence supporting this assertion are the ability of Actr10 to bind mitochondria in the absence of dynactin and the disparate nature of the actr10-dync1h1 and actr10-p150a/b mutant phenotypes in axons. In addition, we identified Drp1, a GTPase implicated in mitochondrial fission, as an Actr10 interactor with a potential role in mitochondrial retrograde transport. Together with previous studies on mitochondrial motility, a complex picture is emerging in which mitochondrial transport and fission/fusion are dependent on a core group of proteins, with an independent set of proteins regulating mitochondrial docking. In conclusion, further work is crucial to understanding how mitochondrial transport and dynamics are orchestrated in axons, which will ultimately allow us to better understand how this critical organelle is positioned and maintained. As mitochondrial transport and dynamics have been implicated in neurological disorders, a more complete mechanistic understanding of their regulation will provide insight into disease pathology.

Adult *AB and WIK strains were maintained at 28.5°C and spawned according to standard protocols (Westerfield, 2000). ENU mutagenesis and mutant screening were performed as described previously (Mullins et al., 1994). Additional strains used include: TgBAC(neurod:egfp)^nl1 (Obholzer et al., 2008), actr10^nl15, dync1h1^mw20 (Insinna et al., 2010), p150a (also known as mok^s309; (Del Bene et al., 2008; Wehman et al., 2005), and p150b^nl16.

RNAseq-based mapping was performed according to established protocols (Miller et al., 2013). actr10 heterozygotes (*AB background) were crossed to WIKs to generate a mapping strain. Heterozygous F1 hybrids were identified using pair wise crosses. Eighty wildtypes/heterozygotes and 80 actr10 mutants were obtained from a single mapping pair. These larvae were lysed at 4 dpf in Trizol according to the manufacturer’s protocol. mRNA was extracted in phenol:chloroform:isoamyl alcohol and twice in chloroform before the pellet was redissolved in 20 µL of RNase/DNase free water. Sequencing was performed by the OHSU Massively parallel sequencing core on an Illumina HiSeq2000, generating approximately 30 million reads per condition. From this RNAseq data, RNAmapper identified a single nucleotide change in the start codon of the actr10 gene in the actr10^nl15 mutant pool. The mutation (validated by sequencing and restriction digest of individual samples) completely segregated with the mutant phenotype. For experiments, actr10 mutants were identified by genotyping according to the following protocol: PCR amplification of the region around exon 1 of the actr10 locus resulted in a 374 bp product (forward primer: 5’-CTGTTTTCGGATGAACTGCCTG; reverse primer: 5’-AGATGCTCTTCGTCTTCTGGCTA. The actr10 mutation inserts a HaeIII cut site. Digestion with HaeIII generates wildtype (209 bp) and actr10 mutant (195 bp) bands.

The full-length open reading frame of actr10 was cloned from a 2 dpf zebrafish cDNA library and ligated into the pSC-A-amp/kan vector (Agilent Technologies; forward primer: 5’-AAATGCCCTTGTTTGAA; reverse primer: 5’-TTTCTCAGTGGAGAAGG). All expression and mRNA synthesis vectors were constructed using Gateway compatible cloning as described (Kwan et al., 2007). For Actr10 expression, the Actr10 open reading frame was PCR amplified with BP arms and inserted into the Gateway compatible 3’-entry vector pDONRP2R-P3 (forward primer: 5’-ggggacaagtttgtacaaaaaagcaggctAAATGCCCTTGTTTGAA; reverse primer: 5’-ggggaccactttgtacaagaaagctgggtaTTTCTCAGTGGAGAAGG). Other constructs used included: 5kbneurod:mito-TagRFP (modified from (Fang et al., 2012); 5kbneurod:mRFP-dync1li1V2 (Drerup and Nechiporuk, 2013); Hsp701:mRFP-polyA; Hsp701:Drp1-mRFP; Hsp701:Drp1^K38A-mRFP; and CMV/SP6:EGFP-dync1i2b. They were constructed as described here. The zebrafish dync1i2b ortholog was cloned into the pDONRP2P3 3’ entry vector using BP-competent primers (forward primer: 5’-ggggacagctttcttgtacaaagtggAGATGGCTCCCGTTTTAGAGAAG; reverse primer: 5’-ggggacaactttgtataataaagttgtTCATGCCTCGTTCTCTGTC) and a 2 dpf zebrafish cDNA library. The zebrafish Drp1 ortholog was cloned from 2 dpf cDNA, sequence verified, and cloned into the pDONR221 middle entry vector using BP cloning (forward primer: 5’-GGGGACAAGTTTGTACAAAAAAGCAGGCTTCAACGCGATGGAGGCTCTTA; reverse primer: 5’-GGGGACCACTTTGTACAAGAAAGCTGGGTACCACAAGTGCGTC). To generate Drp1^K38A, the middle entry vector was mutated to change Lysine 38 to Alanine (forward primer: 5’-CGCAGAGTAGCGGGGCGAGTTCAG; reverse primer: 5’-CCAAAACTGAACTCGCCCCGCTAC). All expression plasmids were constructed by LR cloning using the 5kbneurod (Mo and Nicolson, 2011), CMV/SP6, or Hsp701 5’ entry vectors and the pDestTol2pA2 destination vector. mRNA was synthesized using the SP6 mMessage Machine kit (Life Technologies). TALENs targeting exon 1 of actr10 were designed using freeware (http://www.talendesign.org) and synthesized as described (Dahlem et al., 2012); Tal1 target: AATTTCTGCTGATAAAATGC; Tal2 target: GGGCAGCGGAGGAGA).

The p150b^nl16 mutant was generated using CRISPR/Cas9-mediated genome editing as described (Hwang et al., 2013; Shah et al., 2015). Guide RNA targeting exon 3 (GGCGAGGGCAGCGCTCCCAC) of the p150b locus was produced using a PCR-mediated scaffold method as described (Gagnon et al., 2014). Cas9 mRNA (Chang et al., 2013) was produced using the SP6 mMessage machine kit. Zygotes derived from p150a (moks³⁰⁹) heterozygous outcrosses were injected with 10 pg guide RNA and 100 pg Cas9 mRNA at the one cell stage. Progeny were raised until adulthood and outcrossed to wildtypes to generate larvae. Larvae were genotyped using PCR amplification of the exon 3 locus (forward primer: 5’-CGTGAGTGAGCTCTTGGTCTG; reverse primer: 5’-GCGTCTATAACCATGTTTGACCTTG) and cut with MwoI to identify insertions/deletions. Changes to the guide RNA target result in loss of the MwoI cut site in p150b mutants: wildtype (164 bp + 64 bp) from p150b mutants (224 bp).

In situ hybridization and antibody labeling were done according to established protocols (Drerup and Nechiporuk, 2013). The actr10 open reading frame was used for in situ hybridization. An ~800 base pair portion the 3’UTR of p150a and p150b were used for in situ hybridization of these paralogues. Antibodies used were: α-Dynein heavy chain (Protein Tech; #12345–1-AP); α-p150 (BD Transduction Laboratories; #610473); α-Lamp1 (Iowa Hybridoma Bank, #1D4B); α-pJNK (Cell Signaling Technology, #9251S); α-GFP (Aves Labs Inc., #GFP-1020); α-DsRed (Clontech, #632496); α-Cytochrome c (BD Biosciences, #556432); α-GFP (Fisher Scientific, #A-11122); α-c-myc (Santa Cruz, #sc-40); and α-ATPβ (Abcam; #ab128743).

HEK293T cells (Sigma Aldrich; #12022001; identity authenticated by STR-PCR) were cultured according to standard protocols in DMEM with 50 U/mL Pen-Strep. Cells tested mycoplasma free (MycoAlert Mycoplasma Detection Kit; Lonza; L07-218). This human cell line was used for its transfection ease and results were confirmed in vivo. Transfection was done in a 6-well plate using 2.5 µg total DNA and 5 µL of Lipofectamine2000 per well according to manufacturer’s protocols (Thermo Fisher; #11668027). The mammalian GFP-Actr10 clone was used previously (Yeh et al., 2012) and obtained from Addgene (plasmid #51398). Drp1-myc and Drp1^K38A-myc expression constructs were previously described (Smirnova et al., 2001). GFP-Actr10 deletion constructs were made using the QuikChange II XL Site-Directed Mutagenesis kit (Agilent, #200521).

Mitochondrial fractionation was performed according to established protocols (Prudent et al., 2013). Briefly, for each biological replicate 100 wildtype/heterozygous or actr10^nl15 mutant larvae were disrupted in 700 µL MB buffer (210 mM mannitol, 70 mM sucrose, 1 mM EDTA, 10 mM HEPES pH = 7.5 and protease inhibitors) using a 26 gauge needle. After removal of the input fraction, lysates were subjected to increasing centrifugation speeds to fractionate mitochondria from a heavy and light fractions. The mitochondrial fraction was washed once in fresh MB buffer prior to addition of Laemmli buffer to the pellet and heat denaturation. Extracts were run on a 10% acrylamide gel, transferred to PVDF membrane, and incubated with antibodies prior to developing with the West Pico Substrate (Thermo Fisher; #34080). After initial development, membranes were washed in water and PBS/0.1% Tween prior to incubation with the α-ATPβ antibody.

Axonal transport analyses were done as described (Drerup and Nechiporuk, 2013). Briefly, zygotes were injected with plasmids to express cargos of interest tagged with fluorescent proteins. At 4 dpf, larvae (each a biological replicate) were screened for pLL ganglion expression of cargo fusions and imaged using a 63X/NA1.2 water objective on an FV1000 confocal microscope (Olympus). All imaging was done in a single z-plane, allowing acquisition at 2–4 frames per second, as required by the Nyquist sampling theorem (Nyquist, 1928). Kymograph analyses of cargo movement were performed using Metamorph (Molecular Devices).

Zebrafish larvae at 5 dpf were fixed and prepared for TEM analysis using standard protocols (Czopka and Lyons, 2011). Samples were embedded and sectioned from the tail of the larvae. An ultramicrotome was used to cut 1000 nm sections, which were then stained with Toluidine Blue to ensure the presence of neuromasts. Subsequently, 70 nm sections were cut and placed on copper mesh grids. Grids were stained with uranyl acetate for one hour and then each grid was cleaned with milliQ water for 45 s. The next day, grids were stained with Sato’s lead stain for 15 min and again cleaned with milliQ water. The Washington University Center for Cellular Imaging Jeol JEM-1400 (Jeol USA) electron microscope was used to observe samples and an AMT V601 camera captured images.

Volumetric analyses to determine mean fluorescence intensity of immunolabeling was done using Imaris (Bitplane). For this analysis, a surface rendering was done using expression of the neurod:egfp transgene in axon terminals and the mean fluorescence intensity was determined. Background from the same channel was subtracted prior to analysis. For quantification of western blots, mean intensity of was determined for signal and background using ImageJ. Statistical analyses were done in JMP. Prior to parametric analyses, data normality and variance were determined. Parametric data was analyzed using ANOVAs with Tukey-Kramer HSD contrasts for multiple comparisons. Non-parametric data was analyzed using Wilcoxon/Kruskal Wallis Tests. Image analyses and figure preparation was done using ImageJ, Adobe Photoshop, and Adobe Illustrator.

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

We would like to thank members of the Nechiporuk lab for critique of this work, A Forbes and M Culbertson for curating the screen, and C Riso and E Hunt for zebrafish husbandry. A Miller was instrumental in mapping the actr10^nl15 mutation using RNAmapper. We are indebted to S Lusk for her work in genotyping and maintaining the mutant strains used here. C De Palma provided the myc-Drp1 constructs. Funding to CMD (NINDS/NIH: K99NS086903), AVN (NICHD/NIH: R01HD072844 and OHSU Center for Spatial Systems Biomedicine: GBMEN0245A1), ALH (F31 NS096814 and Philip and Seema Needleman graduate student fellowship), and KRM (Harry Weaver Scholar of the National Multiple Sclerosis Society) supported this work.

Animal experimentation: This study was performed in strict accordance with the recommendations specified in the Oregon Health and Science University Guide for the Care and Use of Laboratory Animals. All animals were handled in accordance with the institutional animal care and use committee (IACUC) protocol # IS00002972.

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.